Posted by Michael Wonder on 23 Dec 2023
Cidara Therapeutics announces European Approval of Rezzayo (rezafungin) for the treatment of invasive candidiasis in adults
22 December 2023 - Approval based on positive results from the pivotal ReSTORE Phase 3 clinical trial and supported by the STRIVE Phase 2 clinical trials and extensive non-clinical development program.
Cidara Therapeutics today announced Rezzayo (rezafungin acetate) has been approved in the European Union for the treatment of invasive candidiasis in adults.
